Blade Clinical Trials

In recognition of the severity of SARS CoV2 acute and chronic morbidity, BLD-2660 will next advance into a trial in patients with COVID-19 pneumonia. Dosing is scheduled to begin soon. Please check back for more details.

---

COVID-19 Pneumonia and Idiopathic Pulmonary Fibrosis

BLD-2660 recently completed a Phase 1 double-blind, randomized, placebo-controlled, multiple cohort, single and multiple ascending dose trial, and demonstrated safety and tolerability in healthy participants (ClinicalTrials.gov NCT03559166).

B-2660-203, a Phase 2 trial to be conducted in Idiopathic Pulmonary Fibrosis (IPF) patients, is planned to commence Q4 2020. This is a multi-center, randomized, double-blind, placebo-controlled trial to be conducted in approximately 24 subjects, treated for 28 days duration. These subjects will be assessed for changes in lung calpain activity and a variety of other biomarkers noted to be important in IPF disease activity (Clinicaltrials.gov NCT04244825).

B-2660-204, a Phase 2 trial in COVID-19 pneumonia patients, initiated in April 2020. This is a multi-center, randomized, double-blind, placebo-controlled trial to be conducted in approximately 120 subjects, treated for 10 days duration. These subjects will be assessed for reduction in viral burden, improvement in cardiopulmonary function, functional recovery and other parameters. (Clinicaltrials.gov NCT04334460).

---

Chronic Liver Disease

Blade’s autotaxin inhibitor, BLD-0409, is now being studied in a Phase 1 double-blind, randomized, placebo-controlled, multiple cohort, single and multiple ascending dose trial to assess safety, tolerability and pharmacokinetics in healthy participants (Clinicaltrials.gov NCT04146805).

BLD-0409 is the lead candidate for the Phase 2 trial in Non-Alcoholic Steatohepatitis (NASH), projected to begin mid 2021.

Another Phase 2 trial will study the effect of BLD-0409 in patients with Impaired Liver Function. This trial is projected to commence in early 2021.